MJA
MJA

Screening for ovarian cancer

Med J Aust 2003; 178 (12): 655-656.

Summary

  • Ovarian cancer is the leading cause of death from gynaecological malignancies.

  • No precancerous lesions have been identified.

  • Bimanual examination has not been proven to be of value as a screening test.

  • Transvaginal ultrasound examination, with or without measurement of CA 125 levels, is currently being evaluated for population screening.

  • Women at high risk of ovarian cancer should be screened annually — with measurement of CA 125 level and transvaginal ultrasound examination.

Please login with your free MJA account to view this article in full

  • Cleola Anderiesz1
  • Michael A Quinn2

  • 1 National Cancer Control Initiative, Carlton, VIC.
  • 2 Frances Perry House, Carlton, VIC.

Correspondence: 

Acknowledgements: 

We are grateful to Dr N Woodrow for the ultrasound image.

Competing interests:

None identified.

  • 1. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer in Australia 1998. Incidence and mortality data for 1998. Canberra: AIHW, 2001: 1-97. (AIHW Catalogue No. CAN-12).
  • 2. Grover SR, Quinn MA. Is there any value in bimanual pelvic examination as a screening test? Med J Aust 1995; 162: 408-410.
  • 3. Bromley B, Goodman H, Benacerraf BR. Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy. Obstet Gynecol 1994; 83: 434-437.
  • 4. Menon U, Jacobs I. Ovarian cancer screening in the general population. Ultrasound Obstet Gynecol 2000; 15: 350-353.
  • 5. Menon U, Jacobs IJ. Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer 2001; 11 (Suppl 1): 3-6.
  • 6. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000; 21 (6 Suppl): 251S-272S.
  • 7. McNeil C. Ovarian cancer screening trials in progress [news]. J Natl Cancer Inst 1995; 87: 1284.
  • 8. Chen WY, Garber JE, Higham S, et al. BRCA1/2 genetic testing in the community setting. J Clin Oncol 2002; 20: 4485-4492.
  • 9. Mills GGB, Vast RC Jnr, Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Int Cancer Inst 2001; 93: 1437-1439.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article